Rotating magnetic field and pulse magnetic field cooperative regulation device

Abstract

A device for the coordinated regulation of rotating and pulsed magnetic fields includes: a magnetic field generating unit, magnetic thrombolytic particles, a control system, and a positioning and navigation module. This invention employs a synergistic design of coaxially nested rotating and pulsed magnetic fields, utilizing both the rotating magnetic field to provide mechanical shearing and the pulsed magnetic field to activate the fibrinolytic system. This synergistic effect not only achieves non-invasive and precise targeted treatment but also overcomes the efficiency bottleneck of a single magnetic field. Combined with real-time image closed-loop feedback and dynamic parameter adjustment, this strategy effectively resolves the contradiction between the difficulty of particle retention and powerful thrombolysis, improving thrombolysis efficiency by more than 30% and achieving efficient, non-invasive, and precise treatment.

Description

Technical Field

[0001] This invention relates to the field of magnetic field thrombolysis technology, specifically to a device for coordinated control of rotating magnetic field and pulsed magnetic field. Background Technology

[0002] Thromboembolic diseases are a leading cause of death and disability worldwide. The core pathological mechanism of acute ischemic stroke, acute myocardial infarction, and other emergencies is the blockage of blood vessels by thrombi, leading to ischemia and hypoxia in tissues and organs. Timely and effective thrombolytic therapy is crucial for improving patient prognosis.

[0003] Currently, the commonly used thrombolysis methods in clinical practice mainly include pharmacolysis and mechanical thrombolysis. Pharmacolysis has drawbacks such as a narrow treatment window, high risk of bleeding, and poor efficacy against old thrombi; while traditional mechanical thrombolysis (such as thrombectomy stents and ultrasound thrombolysis) has problems such as greater invasiveness, potential damage to vascular endothelium, and complex equipment operation.

[0004] Magnetic field thrombolysis, as a novel non-invasive thrombolysis technique, has become a research hotspot due to its advantages of being non-invasive, easy to operate, and highly safe. Current magnetic field thrombolysis techniques mostly employ a single rotating magnetic field or a pulsed magnetic field: a single rotating magnetic field drives magnetic particles to rotate through magnetic force, achieving mechanical shearing of the thrombus, but suffers from limited magnetic field range and insufficient thrombolysis efficiency; a single pulsed magnetic field generates an induced electric field through rapid changes in the magnetic field, destroying the thrombus structure and promoting fibrinolysis system activation, but has drawbacks such as weak magnetic field penetration and poor targeting of the thrombus. Therefore, how to combine the advantages of both magnetic fields to construct a synergistic thrombolysis mechanism, improving thrombolysis efficiency and safety, has become a key bottleneck in the current development of magnetic field thrombolysis technology. Summary of the Invention

[0005] The purpose of this invention is to provide a device for coordinated control of rotating magnetic field and pulsed magnetic field, comprising: magnetic field generating unit, magnetic thrombolytic particles, control system, and positioning and navigation module.

[0006] The magnetic field generating unit includes a rotating magnetic field generating component and a pulsed magnetic field generating component.

[0007] The rotating magnetic field generating component is used to generate a rotating magnetic field.

[0008] The pulsed magnetic field generating component is used to generate a pulsed magnetic field.

[0009] The control system is used to jointly regulate the rotating magnetic field and the pulsed magnetic field to achieve targeted intervention of thrombi.

[0010] The positioning and navigation module is used to locate the position of thrombi in the body and monitor the dissolution of thrombi in real time.

[0011] The magnetic thrombolytic particles are injected into the body via intravenous injection and, guided by a rotating magnetic field, accumulate at the thrombus site.

[0012] When the magnetic thrombolytic particles reach the thrombus location, they rotate under the influence of the rotating magnetic field, generating mechanical shear force on the thrombus and destroying its structure. At the same time, the pulsed magnetic field creates pulsed impacts on the thrombus, loosening the fibrin cross-linking structure of the thrombus and activating the fibrinolytic system in the body, promoting the production of endogenous thrombolytic enzymes.

[0013] Furthermore, the coordinated control device also includes a power supply module.

[0014] The power module includes a high-voltage module and a low-voltage module.

[0015] The high-voltage module is used to power the pulse magnetic field generating component.

[0016] The voltage range of the high-voltage module is 0-1000V.

[0017] The low-voltage module is used to power the rotating magnetic field generating component, the control system, and the positioning and navigation module.

[0018] The voltage range of the low-voltage module is 0-24V.

[0019] Furthermore, the rotating magnetic field generating component includes a rotating magnetic field power supply module, a DC motor, and a rotating permanent magnet.

[0020] The rotating magnetic field power module is used to power the DC motor.

[0021] The DC motor drives the rotating permanent magnet to rotate around its own axis, forming a rotating magnetic field.

[0022] The DC motor has a speed range of 100 r / min - 3000 r / min.

[0023] Furthermore, the rotating permanent magnet is made of neodymium iron boron permanent magnet material.

[0024] Furthermore, the pulsed magnetic field generating component includes a pulsed magnetic field power supply module, an energy storage capacitor, a discharge switch, and a pulse coil.

[0025] The pulsed magnetic field power module is used to charge the energy storage capacitor.

[0026] The energy storage capacitor discharges to the pulse coil through a discharge switch, generating a pulsed magnetic field.

[0027] Furthermore, the surface of the magnetic thrombolytic particles is provided with plasminogen activator and thrombus-targeting molecules.

[0028] The plasminogen activator includes urokinase and tissue-type plasminogen activator.

[0029] The thrombosis-targeting molecules include RGD peptide and fibrin antibody.

[0030] Furthermore, the control system includes a main controller, a rotating magnetic field control module, and a pulsed magnetic field control module.

[0031] The main controller is used to receive the thrombus location and real-time monitoring data transmitted by the positioning and navigation module, and to generate PWM control signals and digital control signals.

[0032] The real-time monitoring data includes thrombus size and thrombus morphology.

[0033] After receiving the PWM control signal, the rotating magnetic field control module adjusts the intensity and rotation frequency of the rotating magnetic field.

[0034] After receiving the digital control signal, the pulse magnetic field control module adjusts the intensity, frequency, and pulse width of the pulse magnetic field.

[0035] Furthermore, the intensity of the rotating magnetic field ranges from 0.001 T to 0.1 T, and the rotation frequency ranges from 0 to 50 Hz.

[0036] The peak magnetic field strength of the pulsed magnetic field ranges from 0.05 T to 0.5 T, the pulse frequency ranges from 1 Hz to 10 Hz, and the pulse width ranges from 10 μs to 1000 μs.

[0037] Furthermore, the positioning and navigation module includes an ultrasonic probe.

[0038] The ultrasound probe is used to monitor the location, size, and shape of the thrombus in real time.

[0039] Furthermore, the rotating magnetic field is applied above the thrombus location region of the organism.

[0040] The pulsed magnetic field is nested and applied to the thrombus location region, and there is a gap between the pulsed magnetic field and the rotating magnetic field.

[0041] The technical effectiveness of this invention is undeniable. It employs a synergistic design of coaxially nested rotating and pulsed magnetic fields, utilizing both the rotating magnetic field to provide mechanical shearing and the pulsed magnetic field to activate the fibrinolytic system. This synergistic effect not only achieves non-invasive, precise targeted therapy but also overcomes the efficiency bottleneck of a single magnetic field: in the delivery stage, the active guiding function of the rotating magnetic field guides magnetic drug-loaded particles to avoid vascular obstacles and precisely accumulate in the thrombus target area; in the treatment stage, a spatial synergistic mechanism of "global anchoring + local strong disruption" is adopted, using the rotating magnetic field to bind particles to the thrombus surface for continuous shearing (preventing particle scattering), combined with the pulsed magnetic field to apply instantaneous high-energy impact to destroy the thrombus structure. Combined with real-time image closed-loop feedback and dynamic parameter adjustment, this strategy effectively solves the contradiction between the difficulty of particle retention and powerful thrombolysis, improving thrombolysis efficiency by more than 30%, achieving efficient, non-invasive, and precise treatment.

[0042] This invention achieves interference-free superposition of rotating magnetic field (mechanical shear) and pulsed magnetic field (induced electric field) in the same space and time by constructing coaxial nested magnetic field generating units. It utilizes a dual mechanism to destroy the fibrin backbone of thrombi, thus significantly improving thrombolysis efficiency.

[0043] This invention utilizes an external magnetic field to drive surface-modified magnetic nanoparticles, achieving non-contact physical thrombolysis. While ensuring the integrity of the vascular endothelium, it significantly reduces the toxic side effects of drugs on normal tissues through precise targeting.

[0044] This invention solves the problem of blind treatment by integrating a positioning and navigation module with a closed-loop control system, ensuring that the magnetic field energy accurately covers the thrombus site and improving the safety and effectiveness of the treatment.

[0045] The beneficial effects of this invention include:

[0046] 1. Synergistic effect and significant efficiency: The coaxial nested structure achieves the superposition of rotating magnetic field (mechanical shearing) and pulsed magnetic field (induced electric field). This dual mechanism directly destroys the thrombus structure and activates the endogenous fibrinolytic system. Compared with single magnetic field technology, the thrombolysis efficiency is improved by more than 30% and the treatment time is shortened.

[0047] 2. Non-invasive, safe, and controllable: Utilizing an external magnetic field, it avoids the mechanical damage to the vascular endothelium caused by traditional interventional surgery. Combined with a closed-loop control system and targeted magnetic particles, it reduces the risk of bleeding and allows for precise parameter adjustment based on the patient's condition, ensuring high treatment safety.

[0048] 3. Simple, low-consumption, and easy to promote: The device has a reasonable structural design and a high degree of automation, and medical staff can operate it after simple training. At the same time, the manufacturing cost of the equipment is relatively low, which is conducive to its popularization and promotion in medical institutions at all levels. Attached Figure Description

[0049] Figure 1 A schematic diagram of a device for coordinated control of rotating magnetic field and pulsed magnetic field;

[0050] Figure 2 This is a diagram of the device for coordinated control of rotating magnetic field and pulsed magnetic field;

[0051] Figure 3 A flowchart for thrombosis treatment;

[0052] Figure 4 Diagram of thrombosis treatment plan;

[0053] Figure 5 A schematic diagram of a physical object demonstrating the synergistic thrombolysis effect of rotating magnetic field and pulsed magnetic field;

[0054] In the diagram: 1. Rotating magnetic field; 2. In vitro blood clot; 3. Pulsed magnetic field; 4. Experimental group; 5. Control group. Detailed Implementation

[0055] The present invention will be further described below with reference to embodiments, but it should not be construed that the scope of the present invention is limited to the following embodiments. Various substitutions and modifications made based on ordinary technical knowledge and common practices in the art without departing from the above-described technical concept of the present invention should be included within the scope of protection of the present invention.

[0056] Example 1:

[0057] See Figures 1 to 5 A rotating magnetic field and pulsed magnetic field coordinated control device includes: a magnetic field generating unit, magnetic thrombolytic particles, a control system, and a positioning and navigation module.

[0058] The magnetic field generating unit includes a rotating magnetic field generating component and a pulsed magnetic field generating component.

[0059] The rotating magnetic field generating component is used to generate a rotating magnetic field.

[0060] The pulsed magnetic field generating component is used to generate a pulsed magnetic field.

[0061] The control system is used to jointly regulate the rotating magnetic field and the pulsed magnetic field to achieve targeted intervention of thrombi.

[0062] The positioning and navigation module is used to locate the position of thrombi in the body and monitor the dissolution of thrombi in real time.

[0063] The magnetic thrombolytic particles are injected into the body via intravenous injection and, guided by a rotating magnetic field, accumulate at the thrombus site.

[0064] When the magnetic thrombolytic particles reach the thrombus location, they rotate under the influence of the rotating magnetic field, generating mechanical shear force on the thrombus and destroying its structure. At the same time, the pulsed magnetic field creates pulsed impacts on the thrombus, loosening the fibrin cross-linking structure of the thrombus and activating the fibrinolytic system in the body, promoting the production of endogenous thrombolytic enzymes.

[0065] Example 2:

[0066] A rotating magnetic field and pulsed magnetic field coordinated control device is described in Embodiment 1. Furthermore, the coordinated control device also includes a power supply module.

[0067] The power module includes a high-voltage module and a low-voltage module.

[0068] The high-voltage module is used to power the pulse magnetic field generating component.

[0069] The voltage range of the high-voltage module is 0-1000V.

[0070] The low-voltage module is used to power the rotating magnetic field generating component, the control system, and the positioning and navigation module.

[0071] The voltage range of the low-voltage module is 0-24V.

[0072] Example 3:

[0073] A rotating magnetic field and pulsed magnetic field coordinated control device, the main technical contents of which are described in any one of Embodiments 1 to 2, further wherein the rotating magnetic field generating component includes a rotating magnetic field power supply module, a DC motor, and a rotating permanent magnet.

[0074] The rotating magnetic field power module is used to power the DC motor.

[0075] The DC motor drives the rotating permanent magnet to rotate around its own axis, forming a rotating magnetic field.

[0076] The DC motor has a speed range of 100 r / min - 3000 r / min.

[0077] Example 4:

[0078] A rotating magnetic field and pulsed magnetic field coordinated control device, the main technical contents of which are described in any one of Embodiments 1 to 3, further wherein the rotating permanent magnet is made of neodymium iron boron permanent magnet material.

[0079] Example 5:

[0080] A rotating magnetic field and pulsed magnetic field coordinated control device, the main technical contents of which are described in any one of embodiments 1 to 4. Further, the pulsed magnetic field generating component includes a pulsed magnetic field power supply module, an energy storage capacitor, a discharge switch, and a pulse coil.

[0081] The pulsed magnetic field power module is used to charge the energy storage capacitor.

[0082] The energy storage capacitor discharges to the pulse coil through a discharge switch, generating a pulsed magnetic field.

[0083] Example 6:

[0084] A rotating magnetic field and pulsed magnetic field synergistic control device, the main technical contents of which are described in any one of Examples 1 to 5, further wherein the surface of the magnetic thrombolytic particles is provided with plasminogen activator and thrombus targeting molecules.

[0085] The plasminogen activator includes urokinase and tissue-type plasminogen activator.

[0086] The thrombosis-targeting molecules include RGD peptide and fibrin antibody.

[0087] Example 7:

[0088] A rotating magnetic field and pulsed magnetic field coordinated control device, the main technical contents of which are described in any one of Embodiments 1 to 6, further wherein the control system includes a main controller, a rotating magnetic field control module and a pulsed magnetic field control module.

[0089] The main controller is used to receive the thrombus location and real-time monitoring data transmitted by the positioning and navigation module, and to generate PWM control signals and digital control signals.

[0090] The real-time monitoring data includes thrombus size and thrombus morphology.

[0091] After receiving the PWM control signal, the rotating magnetic field control module adjusts the intensity and rotation frequency of the rotating magnetic field.

[0092] After receiving the digital control signal, the pulse magnetic field control module adjusts the intensity, frequency, and pulse width of the pulse magnetic field.

[0093] Example 8:

[0094] A rotating magnetic field and pulsed magnetic field coordinated control device, the main technical contents of which are described in any one of Embodiments 1 to 7, further wherein the intensity range of the rotating magnetic field is 0.001 T - 0.1 T and the rotation frequency range is 0-50 Hz.

[0095] The peak magnetic field strength of the pulsed magnetic field ranges from 0.05 T to 0.5 T, the pulse frequency ranges from 1 Hz to 10 Hz, and the pulse width ranges from 10 μs to 1000 μs.

[0096] Example 9:

[0097] A rotating magnetic field and pulsed magnetic field coordinated control device, the main technical contents of which are described in any one of Embodiments 1 to 8, further wherein the positioning and navigation module includes an ultrasonic probe.

[0098] The ultrasound probe is used to monitor the location, size, and shape of the thrombus in real time.

[0099] Example 10:

[0100] A rotating magnetic field and pulsed magnetic field coordinated control device, the main technical contents of which are described in any one of embodiments 1 to 9, further wherein the rotating magnetic field is applied above the thrombus location area of ​​the organism.

[0101] The pulsed magnetic field is nested and applied to the thrombus location region, and there is a gap between the pulsed magnetic field and the rotating magnetic field.

[0102] Example 11:

[0103] See Figures 1 to 5 A rotating magnetic field and pulsed magnetic field coordinated control device, the main technical contents of which include:

[0104] The magnetic field control system in this embodiment uses a magnetic field excitation source as the core driving unit. On the one hand, it generates a pulsed magnetic field through a coil excitation module, and on the other hand, it constructs a rotating magnetic field through a permanent magnet excitation module. The two types of magnetic field signals are uniformly fed into a composite magnetic pulse control unit. This unit coordinates and dynamically adjusts the parameters (such as frequency, amplitude, and phase) of the pulsed magnetic field and the rotating magnetic field, and finally forms a composite magnetic pulse signal that is adapted to the magnetic particle control requirements and acts on the target magnetic particle. Through this multi-source magnetic field fusion control mechanism, precise dynamic control of magnetic particles is achieved, providing stable and controllable magnetic field intervention support for subsequent applications such as magnetic particle-based thrombosis treatment.

[0105] The magnetic field control device in this embodiment uses an integrated magnetic field excitation source as its core. Internally, it comprises two independent magnetic field generation systems: one consisting of a high-voltage power supply, a discharge module, and an electromagnetic coil connected sequentially. The high-voltage power supply provides energy reserves for the discharge module, which inputs pulsed current to the electromagnetic coil through instantaneous discharge, thereby generating a pulsed magnetic field with precisely adjustable parameters. The other system consists of a low-voltage power supply, a DC motor, and a rotating permanent magnet. The low-voltage power supply drives the DC motor, and the output shaft of the DC motor is directly connected to the rotating permanent magnet. The motor drives the permanent magnet to rotate continuously, generating a rotating magnetic field with periodically changing direction. Simultaneously, the device controls magnetic microparticles loaded with thrombolytic drugs. Through the synergistic effect of the pulsed and rotating magnetic fields, it achieves directional driving and thrombolytic intervention of the magnetic drug-loaded microparticles. The modular structural design of this device ensures both the independence and parameter adjustability of the two magnetic field generation methods while achieving an integrated layout of the magnetic field excitation source, providing stable and controllable magnetic field intervention support for magnetic microparticle-mediated thrombolytic therapy.

[0106] The specific operation of the magnetic particle-mediated thrombosis treatment process involved in this embodiment is as follows: First, functionalized magnetic particles are precisely introduced into the patient's circulatory system via vascular interventional injection. The particles are initially carried towards the vascular segment where the thrombus is located by blood flow. Then, an external rotating magnetic field generator is activated. The magnetic field's directional traction effect guides the particles dynamically, and by adjusting the rotational angular velocity and direction of the magnetic field in real time, the particle's movement path within the blood vessel is corrected, enabling it to avoid complex structures such as vascular branches and directionally approach the thrombus target area. During this process, the magnetic particles are captured in real time by an in vivo magnetic signal monitoring module. If the spatial location information is used, and it is determined that the particles have not yet reached the thrombus target area, the guiding effect of the rotating magnetic field is continuously maintained. After the particles successfully reach the target area and accumulate, the magnetic field control mode is switched, and a composite magnetic pulse with preset parameters is applied to the thrombus area (the relative strength of the pulse and the rotating magnetic field is adjusted according to the effect). With the help of the vibration and clustering effect of the magnetic pulse on the magnetic particles, the particles are prompted to perform thrombolysis-related actions inside the thrombus. At the same time, the treatment progress is judged by the real-time assessment module of the thrombus dissolution status. If the preset thrombolysis effect is not achieved, the composite magnetic pulse is continuously applied in a loop to enhance the intervention. After the treatment is completed, all magnetic field control operations are terminated, and the entire treatment process is completed. This process, through the phased precise magnetic field control strategy of "magnetic navigation targeted delivery - magnetic pulse targeted intervention", not only achieves efficient and specific delivery of magnetic particles from the blood circulation to the thrombus target area, but also enhances the thrombolysis efficacy of the particles in the thrombus area by relying on the dynamic effect of the magnetic pulse, effectively improving the targeting, safety and overall intervention effect of the treatment.

[0107] In this embodiment, the rotating magnetic field generated by the magnet containing S and N poles acts on the entire area of ​​the vertically arranged magnetic drug-loaded particles or magnetic particle clusters in a fully covered manner. The magnetic field range completely envelops the vertical space of the particle cluster. Through the continuous rotation and transformation of the magnetic field direction, on the one hand, a circumferential binding force is formed on the particles, which stably anchors the dispersed particles in the thrombus target area within the horizontal blood vessel and maintains their close adhesion to the thrombus. On the other hand, the periodic dynamic change of the magnetic field force transmits a continuous and uniform shearing force to the particles, assisting the particles in continuously mechanically loosening the thrombus fibrous network. Meanwhile, the pulsed magnetic field generated by the pulsed electromagnetic coil focuses precisely on the lateral overlap area between the particle cluster and the thrombus target area. The magnetic field range is highly matched with the lateral distribution area of ​​the thrombus. Through the sudden change of the pulsed magnetic field strength, an instantaneous strong shearing force is provided to the particles in this local area, achieving concentrated mechanical destruction of the thrombus. Structurally, an array of permanent magnets that generates a rotating magnetic field is placed above the active area, while a hollow cylindrical coil that generates a pulsed magnetic field is nested within the active area, with a specific gap (more than 10 mm) maintained between them to avoid mechanical interference. This compact spatial reuse design ensures that the rotating magnetic field and the pulsed magnetic field can achieve precise and interference-free superposition in the target area at the front end, forming a stable synergistic magnetic field active area, cleverly solving the structural problem of superimposing two magnetic fields of different properties in the same space.

[0108] Based on a relative position matching design of "rotating magnetic field for full-domain encapsulation and anchoring + continuous shearing, pulsed magnetic field for local targeted strong shearing", the two technologies solve the problem of particle anchoring stability in the thrombus area by relying on the full-domain coverage of the rotating magnetic field, and enhance the precision of shearing effect by the local targeting effect of the pulsed magnetic field. Through the synergistic effect of "continuous loosening + instantaneous strong breaking", the magnetic drug-loaded particles can not only remain in the thrombus area for a long time to exert a continuous effect, but also form a highly efficient mechanical shearing effect in key areas. At the same time, the drug-loaded properties of the particles can simultaneously achieve targeted drug release, which significantly improves the targeting, sustainability and overall intervention effect of thrombolytic therapy.

[0109] Combined with appendix Figure 1 (System overall structure diagram), Appendix Figure 2 (Diagram of magnetic field excitation device) and appendix Figure 3 (Treatment flowchart) The device includes a magnetic field generating unit, magnetic thrombolytic particles, a control system, a power supply module, and a positioning and navigation module. The connection relationships and structures of each part are as follows:

[0110] Magnetic field generating unit: This is the core actuator of the device, used to simultaneously generate a rotating magnetic field and a pulsed magnetic field. It includes a rotating magnetic field generating component and a pulsed magnetic field generating component, both configured within a single system framework (as shown in the attached diagram). Figure 2(As shown in the schematic diagram of the magnetic field generating unit structure), forming a synergistic magnetic field action region; rotating magnetic field generating component: combined with attached... Figure 2 The component includes a low-voltage power supply, a DC motor, and a rotating permanent magnet. The DC motor is rigidly connected to the permanent magnet via a coupling, driving the rotating permanent magnet to rotate stably around its own axis. The permanent magnet is fixed to the free end of the rotating shaft, and its magnetic poles are evenly and symmetrically distributed along the circumference. (See attached image) Figure 2 The image shows a uniformly distributed magnet structure. When the rotating shaft drives the permanent magnet to rotate, a stable rotating magnetic field is formed in a preset area in front of it. The permanent magnet uses neodymium iron boron high-performance permanent magnet material, according to the attached... Figure 2 According to the magnet parameters marked in the figure and the actual test, the intensity of the rotating magnetic field generated at a distance of 2cm can be adjusted from 0.001 to 0.1T.

[0111] Pulse magnetic field generating component: combined with attached Figure 2 The component includes a high-voltage power supply, a discharge switch, and a pulse coil. The pulse coil is a hollow cylindrical helical coil. The high-voltage power supply charges the capacitor, and the discharge switch then discharges the capacitor into the coil. (See attached image.) Figure 2 The coil turns and wire diameter parameters are marked in the figure. The peak magnetic field strength of the pulsed magnetic field can be adjusted from 0.05 to 0.5T, the pulse frequency can be adjusted from 1 to 10Hz, and the pulse width can be adjusted from 10 to 1000μs.

[0112] Magnetic thrombolytic particles: These are functional particles that can be driven by a magnetic field and are used to target the thrombus site; combined with... Figure 1 The schematic diagram of the overall device structure illustrates the targeted aggregation of particles with a diameter of 50-5000 nm. The surface is modified with plasminogen activators (such as urokinase and tissue-type plasminogen activator) and thrombus-targeting molecules (such as RGD peptide and fibrin antibody). The magnetic thrombolytic particles can be injected intravenously and, guided by a rotating magnetic field positioning and navigation module, precisely aggregate at the thrombus site (see attached diagram). Figure 1 The target path of the particles (from the injection end to the thrombus site) is visible, and under the influence of the synergistic magnetic field, they generate multimodal motions such as rotation.

[0113] Power module: combined with the attached Figure 2 The overall structure of the device is shown in the schematic diagram. The module includes a high-voltage power supply interface and a low-voltage DC power supply interface. The low-voltage DC power supply interface supplies power to all electrical components such as the DC motor drive, control system, and positioning and navigation module. The high-voltage power supply interface supplies power to the capacitors in the pulse magnetic field generating circuit. Therefore, the dual power supply system meets the differentiated power supply needs of each component and has overvoltage and overcurrent protection functions.

[0114] Control system: the core control component of the device, combined with attached... Figure 1 and attached Figure 2The control system principle block diagram includes a main controller, a rotating magnetic field control module, and a pulsed magnetic field control module. The main controller uses an STM32 series microcontroller as the control core and is bidirectionally connected to the rotating magnetic field control module, the pulsed magnetic field control module, the positioning and navigation module, and the power supply module.

[0115] Rotating magnetic field control module: Electrically connected to the drive motor, according to the control logic in the attached diagram, it can receive the PWM control signal from the main controller, adjust the speed of the drive motor (adjustable range is 100-3000r / min), and thus accurately control the rotation frequency of the rotating magnetic field. The speed feedback signal can be sent back to the main controller in real time to achieve closed-loop control.

[0116] Pulse magnetic field control module: Electrically connected to the pulse coil, this module adopts a full-bridge inverter circuit structure, which can receive digital control signals from the main controller, generate pulse current with adjustable parameters, and then adjust the intensity, frequency and pulse width of the pulse magnetic field. The peak value, frequency and other parameters of the pulse current can be fed back to the main controller through the sampling circuit to achieve precise control of the pulse magnetic field.

[0117] Main controller: Based on the information such as the location and size of the thrombus fed back by the positioning and navigation module and the patient's clinical parameters, it can automatically match the synergistic parameters of the rotating magnetic field and the pulsed magnetic field to ensure the thrombolysis effect and safety.

[0118] Based on the above device, combined with the attached Figure 1-3 In addition to the structural and principle information, this embodiment also provides a thrombolysis method, the specific steps of which are as follows:

[0119] Preoperative preparation: The patient undergoes imaging examinations (such as ultrasound and CT) to determine the location, size, and shape of the thrombus; combined with... Figure 2 The overall layout of the device involves fixing the magnetic field generating unit to the corresponding position on the treatment bed. The ultrasound probe of the positioning and navigation module acquires images of the thrombus, which are then analyzed by the image processing unit to calibrate the magnetic field's effective area, ensuring precise coverage of the thrombus site. (See attached image) Figure 4 (Correspondence between the magnetic field generating unit and the thrombus site); check the connection status and working performance of each component of the device, especially confirming that the communication connection between the drive motor, pulse electromagnetic coil and control system is normal, to ensure the normal operation of the equipment.

[0120] Targeted drug delivery: Magnetic thrombolytic particles are injected into the patient's body via intravenous injection; combined with the guidance of a rotating magnetic field to target the particles, the magnetic thrombolytic particles specifically aggregate at the thrombus site under the action of the target molecules on their surface, thus achieving targeted localization.

[0121] Coordinated magnetic field initiation: The rotating magnetic field generator and the pulsed magnetic field generator are activated through the control system; combined with the attached... Figure 2 and attached Figure 3The principle is that the drive motor rotates the permanent magnet array, generating a rotating magnetic field that drives the magnetic thrombolytic particles at the thrombus site to rotate synchronously, generating mechanical shear force on the thrombus fibrin network and destroying the thrombus structure. At the same time, a pulse current is passed through the pulse coil to generate a pulse magnetic field, forming a pulse impact in the thrombus area. On the one hand, this further loosens the cross-linked structure of the thrombus fibrin, and on the other hand, it activates the fibrinolytic system in the patient's body, promoting the production of endogenous thrombolytic enzymes. By controlling the rotation speed of the rotating magnetic field and the intensity and frequency of the pulse magnetic field, the two magnetic fields work synergistically to improve the thrombolytic efficiency.

[0122] Intraoperative monitoring: During the treatment process, combined with the appendix Figure 3 The system uses an ultrasound probe in the positioning and navigation module to acquire thrombus images in real time. The image processing unit dynamically analyzes the thrombus dissolution and the distribution of magnetic thrombolytic particles. Based on the monitoring results, the control system dynamically adjusts the parameters of the rotating magnetic field and the pulsed magnetic field to ensure the safety and effectiveness of the thrombolysis process. At the same time, the system monitors the patient's vital signs (such as heart rate, blood pressure, and coagulation function). If any abnormality occurs, the treatment is stopped immediately.

[0123] Postoperative management: After thrombolytic therapy is completed, turn off the magnetic field generating unit and stop drug administration; perform postoperative imaging examinations on the patient to assess the thrombolytic effect; if the thrombus is not completely dissolved, the above treatment steps can be repeated until the expected therapeutic effect is achieved.

[0124] Example 12:

[0125] See Figures 1 to 5 A rotating magnetic field and pulsed magnetic field coordinated control device, the main technical contents of which include:

[0126] like Figure 1-3 As shown, this embodiment provides a thrombolysis device based on the synergy of a rotating magnetic field and a pulsed magnetic field, including a magnetic field generating unit, magnetic thrombolysis particles, a control system, a power supply module, and a positioning and navigation module.

[0127] The rotating magnetic field generating component includes a servo motor (model SG-M202A) with an adjustable speed range of 100-3000 r / min as the drive motor; and a permanent magnet array consisting of a single neodymium iron boron permanent magnet, evenly distributed around the circumference of the two ends of the rotating shaft (see attached diagram). Figure 2 (Structural diagram), the maximum magnetic field strength is 0.5T; the pulse coil is wound with copper enameled wire, with 500 turns and an inner diameter of 50mm (see attached diagram). Figure 2The system uses a coil structure to generate a pulsed magnetic field with a peak value of 1.0T when a pulsed current is applied. The pulse frequency is adjusted by the pulsed magnetic field control module, ranging from 1-100Hz. The main controller in the control system uses an STM32F407 microcontroller, the rotating magnetic field control module uses a motor driver (model L298N), and the pulsed magnetic field control module uses a full-bridge inverter circuit (see attached diagram). Figure 3 The control module structure is composed of IGBT transistors; the ultrasonic probe in the positioning and navigation module is a linear array probe with a frequency of 5-12MHz, and the image processing unit 12 uses an FPGA chip, model XC7K325T.

[0128] The specific steps of the thrombolysis method in this embodiment are as follows:

[0129] Preoperative preparation: A brain ultrasound is performed on patients with acute ischemic stroke to determine the location and size of the thrombus in the middle cerebral artery; combined with... Figure 1 The device layout involves fixing the magnetic field generating unit at the head of the treatment bed. Thrombus images are acquired through an ultrasound probe, and the image processing unit analyzes the images and feeds the positioning information back to the main controller. The main controller adjusts the position of the magnetic field generating unit so that the synergistic magnetic field area accurately covers the thrombus site. All components of the device are inspected to ensure that the drive motor, pulse coil, etc. are working properly.

[0130] Targeted drug delivery: Magnetic thrombolytic particles (200 nm in diameter) with a surface modified with tissue plasminogen activator and RGD peptide are injected into the patient via intravenous injection at a dose of 5 mg / kg; wait 30 minutes for the magnetic thrombolytic particles to aggregate at the thrombus site under the action of the targeted molecules.

[0131] Synergistic magnetic field initiation: The main controller sends a control signal to activate the rotating magnetic field control module and the pulsed magnetic field control module; the drive motor speed is adjusted to 1500 r / min, causing the permanent magnet array to rotate and generate a 0.5T rotating magnetic field; the pulsed magnetic field control module is adjusted to allow a pulse current with a peak value of 200A to be passed through the pulse coil, generating a pulsed magnetic field with a peak value of 1T, a frequency of 1Hz, and a pulse width of 500μs; the two magnetic fields are superimposed at the thrombus site (see attached diagram). Figure 2 (Schematic diagram of the synergistic region), driving the magnetic thrombolytic particles to rotate and generate a pulse response to achieve synergistic thrombolysis. The experimental setup and results are as follows: Figure 5 Among them, rotating magnetic field 1, in vitro blood clot 2, pulsed magnetic field 3, experimental group 4, and control group 5.

[0132] Intraoperative monitoring: During the treatment, the ultrasound probe acquires thrombus images in real time, and the image processing unit dynamically analyzes the thrombus dissolution. If the thrombus dissolution rate is found to be too slow, the main controller automatically increases the rotation speed of the rotating magnetic field to 2000 r / min and the intensity of the pulsed magnetic field to 1.5T. At the same time, the patient's heart rate, blood pressure and coagulation function are monitored to ensure that there are no abnormalities.

[0133] Postoperative management: After 60 minutes of treatment, the magnetic field generating unit was turned off and the treatment was stopped; a brain CT scan was performed on the patient, which showed that the thrombus was completely dissolved and the blood vessels were reopened; the patient was observed for 24 hours after the operation and had no adverse reactions such as bleeding, and the treatment was completed.

Claims

1. A device for coordinated control of rotating magnetic field and pulsed magnetic field, characterized in that, include: Magnetic field generating unit, magnetic thrombolytic particles, control system, positioning and navigation module; The magnetic field generating unit includes a rotating magnetic field generating component and a pulsed magnetic field generating component; The rotating magnetic field generating component is used to generate a rotating magnetic field; The pulsed magnetic field generating component is used to generate a pulsed magnetic field; The control system is used to jointly regulate the rotating magnetic field and the pulsed magnetic field to achieve targeted intervention of thrombi; The positioning and navigation module is used to locate the position of thrombi in the body and monitor the dissolution of thrombi in real time. The magnetic thrombolytic particles are injected into the body via intravenous injection and, guided by a rotating magnetic field, accumulate at the thrombus site. When the magnetic thrombolytic particles reach the thrombus location, they rotate under the influence of the rotating magnetic field, generating mechanical shear force on the thrombus and destroying its structure. At the same time, the pulsed magnetic field creates pulsed impacts on the thrombus, loosening the fibrin cross-linking structure of the thrombus and activating the fibrinolytic system in the body, promoting the production of endogenous thrombolytic enzymes.

2. The rotating magnetic field and pulsed magnetic field coordinated control device according to claim 1, characterized in that, The coordinated control device also includes a power module; The power module includes a high-voltage module and a low-voltage module; The high-voltage module is used to power the pulse magnetic field generating component; The voltage range of the high-voltage module is 0-1000V; The low-voltage module is used to power the rotating magnetic field generating component, the control system, and the positioning and navigation module. The voltage range of the low-voltage module is 0-24V.

3. The rotating magnetic field and pulsed magnetic field coordinated control device according to claim 1, characterized in that, The rotating magnetic field generating component includes a rotating magnetic field power supply module, a DC motor, and a rotating permanent magnet; The rotating magnetic field power module is used to power the DC motor; The DC motor drives the rotating permanent magnet to rotate around its own axis, forming a rotating magnetic field; The DC motor has a speed range of 100 r / min - 3000 r / min.

4. The rotating magnetic field and pulsed magnetic field coordinated control device according to claim 3, characterized in that, The rotating permanent magnet is made of neodymium iron boron permanent magnet material.

5. The rotating magnetic field and pulsed magnetic field coordinated control device according to claim 1, characterized in that, The pulsed magnetic field generating component includes a pulsed magnetic field power supply module, an energy storage capacitor, a discharge switch, and a pulse coil; The pulsed magnetic field power module is used to charge the energy storage capacitor; The energy storage capacitor discharges to the pulse coil through a discharge switch, generating a pulsed magnetic field.

6. The rotating magnetic field and pulsed magnetic field coordinated control device according to claim 1, characterized in that, The surface of the magnetic thrombolytic particles is provided with plasminogen activator and thrombus-targeting molecules. The plasminogen activator includes urokinase and tissue-type plasminogen activator; The thrombosis-targeting molecules include RGD peptide and fibrin antibody.

7. The rotating magnetic field and pulsed magnetic field coordinated control device according to claim 1, characterized in that, The control system includes a main controller, a rotating magnetic field control module, and a pulsed magnetic field control module; The main controller is used to receive the thrombus location and real-time monitoring data transmitted by the positioning and navigation module, and to generate PWM control signals and digital control signals; The real-time monitoring data includes thrombus size and thrombus morphology; After receiving the PWM control signal, the rotating magnetic field control module adjusts the intensity and rotation frequency of the rotating magnetic field. After receiving the digital control signal, the pulse magnetic field control module adjusts the intensity, frequency, and pulse width of the pulse magnetic field.

8. The rotating magnetic field and pulsed magnetic field coordinated control device according to claim 7, characterized in that, The intensity of the rotating magnetic field ranges from 0.001T to 0.1T, and the rotation frequency ranges from 0 to 50Hz. The peak magnetic field strength of the pulsed magnetic field ranges from 0.05 T to 0.5 T, the pulse frequency ranges from 1 Hz to 10 Hz, and the pulse width ranges from 10 μs to 1000 μs.

9. The rotating magnetic field and pulsed magnetic field coordinated control device according to claim 1, characterized in that, The positioning and navigation module includes an ultrasonic probe; The ultrasound probe is used to monitor the location, size, and shape of the thrombus in real time.

10. The rotating magnetic field and pulsed magnetic field coordinated control device according to claim 1, characterized in that, The rotating magnetic field is applied above the thrombus location region of the organism; The pulsed magnetic field is nested and applied to the thrombus location region, and there is a gap between the pulsed magnetic field and the rotating magnetic field.

Images